Barinthus Biotherapeutics

Update in progress

BRNS (NasdaqCM)

Barinthus Biotherapeutics plc and its subsidiaries develop immunotherapies and vaccines in the US and UK. It leads VTP-1000, a Phase I immune tolerance candidate for gluten in celiac disease, and VTP-300, a Phase II immunotherapy for chronic hepatitis B. It licenses thermo-responsive adjuvant scaffolds from Oxford University Innovation and collaborates with the NIH on vaccine tech for infectious disease and cancer in animals. Formerly Vaccitech plc, renamed in Nov 2023. Founded 2016; based in Germantown, Maryland.